Our people

Board members

Dr Muchnicki was appointed to the Board on 31 January 2018 and appointed Interim Chief Executive Officer as of 24 September 2019. George graduated from Monash University and has held positions in private practice for over 25 years and was Head of Student Health at The University of Melbourne. For the past 14 years he has been involved in commercialisation and funding R&D in the biotechnology sector from gene silencing to regenerative medicine.

Dr Muchnicki brings with him strong commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry.

Dr. Jerzy “George” Muchnicki 
Executive Director & Chief Executive Officer (Interim)

Dr Wakefield was appointed to the Board on 24 September 2014. He started Safetech in 1985 and over the next 25 years Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial products. In 1993, he left medicine to become the full time CEO of Safetech. In 2006 Safetech was awarded the Telstra Australian National Business of the Year. In 2013 Safetech merged and ultimately acquired Tieman Materials Handling.


Dr Wakefield continues as the CEO of Safetech. It is Australia’s largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years.

Dr. Lindsay Wakefield
Non – Executive Director

Mr Rubinstein was appointed to the Board on 31 January 2018. He has over 20 years’ experience in early stage technology commercialisation through to public listings on the ASX. He is a lawyer, having worked at a large national firm prior to moving in-house at Montech, the commercial arm of Monash University.


Mr Rubinstein has had significant exposure to the creation, launch and management of a diverse range of technology companies in biotech, digital payments and renewable energy. Mr Rubinstein is also Chairman of DigitalX Limited (ASX: DCC).

Mr. Peter Rubinstein 
Non – Executive Director

Mr Burrows was appointed to the Board on 1st September 2019. He is a contemporary independent Non-Executive Director across the Listed, Government and Private sectors with significant expertise in corporate governance, and strategic, commercial, financial and risk management oversight.

Mr Burrows was Chief Financial Officer and Company Secretary of Tassal Group Limited for 21 years from 1988 to 2009. His current diverse multi-sector portfolio includes Non-Executive Directorships of Clean Seas Seafood Limited, TasWater and a number of private companies.

Mr Nick Burrows 
Non – Executive Director

Senior management

Mr Phillip Hains

Chief Financial Officer

Mr Hains was appointed to the role of Chief Financial Officer on July 15, 2019. Phillip is the founder of The CFO Solution, a professional service firm focused on the needs of listed public companies. He has approximately 20 years’ experience in roles with a portfolio of ASX and NASDAQ listed companies. The CFO Solution has a team of finance professionals to support the plans of the Company.

Mr Justyn Stedwell

Company Secretary

Mr Stedwell was appointed to the role of Company Secretary on July 15, 2019. Justyn is a professional Company Secretary consultant with over 10 years experience acting as a Company Secretary of ASX listed companies across a wide range of industries.He is currently the Company Secretary of several ASX listed companies.

Dr Richard Allman 
Chief Scientific Officer

Dr Allman joined the Company in 2004 and was appointed Scientific Director in December 2012. He has over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia. He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics, and product development. Prior to entering the biotech sector, Dr Allman’s academic career encompassed oncology research, drug development, and assay design.


© Genetic Technologies Limited 2020